Search

Displaying results 5011 - 5020 of 10000 in total
  1. Drug

    Ripisartan

    go.drugbank.com/drugs/DB20229
    Experimental

    The usage of the INN stem '-sartan' in the name indicates that Ripisartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  2. Drug

    Dihydrofolic Acid

    go.drugbank.com/drugs/DB02015
    Investigational

    Mixtures: EnLyte Extra-LN
  3. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly.

  4. Drug

    Osoresnontrine

    go.drugbank.com/drugs/DB16274
    Investigational

    in Patients With Schizophrenia on Stable Antipsychotic Treatment.). … Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks

  5. Drug

    Mitometh

    go.drugbank.com/drugs/DB12117
    Investigational

    Mitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others

  6. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of

  7. Drug

    Iofetamine I-123

    go.drugbank.com/drugs/DB09480
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). … This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation.

  9. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  10. Drug

    Caviar, unspecified

    go.drugbank.com/drugs/DB14241
    Approved

    Caviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.